Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Successful challenge to the selection of a drug for AbbVie
We secured the first successful challenge to price controls under the Drug Price Negotiation Program
Olympus $500 million senior notes offering
We advised Olympus on the offering
ADC Therapeutics $86 million private placement
We advised ADC Therapeutics on the transaction involving its common shares and pre-funded warrants
Kodiak Sciences $350 million at-the-market offering
We advised the sales agent on the offering
QIAGEN $12.1 billion takeover offer by EQT Private Equity
We are advising QIAGEN on the transaction
Alector $75 million registered direct offering
We advised the underwriters on the offering
TCGX Acquisition Corp. II $100 million SPAC IPO
We advised the sole bookrunning manager on the IPO
Recursion Pharmaceuticals $200 million follow-on offering
We advised the underwriters on the offering
Medtronic splits off MiniMed
This transaction completes Medtronic’s separation of its diabetes unit
McKesson $1.4 billion investment in Option Care Health
We are advising McKesson on the transaction